Evolv Technology Q3 2026 Earnings Call - EVOLV TECHNOLOGIES HOLDINGS INC

Explicit Guidance:

• 2026 Revenue: Updated range to $182–$195 million (up from prior $180–$165 million guidance), representing 25–27% year-over-year growth; full-year Adjusted EBITDA margins expected in the high single digits (vs. 7.6% in 2025).
• 2026 ARR: Reaffirmed year-end Annual Recurring Revenue guidance of $148–$150 million, representing 23–25% year-over-year growth.
• 2027 Revenue: Expect reported revenue growth of 20% or more in 2027; this outlook includes a 3–4 percentage point headwind driven by the shift of contract value from upfront product revenue to recurring revenue.
• Long-Term Growth: Confirmed expectation for revenue to grow at a compound annual rate (CAGR) of approximately 25% through 2031, with growth building toward this rate as sales investments ramp.
• 2027 Margins: Expect continued modest expansion in Adjusted EBITDA margins in 2027, pending finalization of the operating plan to be provided in Q4 2026.
• Unit Deployments: Expect to deploy more units in 2027 than in 2026, with incremental units from investments arriving in the second half of 2027.

Business-Segment Outlook:

• Product Mix & Pricing: Strategic shift from upfront product revenue to recurring revenue (subscription) is ongoing; new pricing changes implemented in July 2025 (lower hardware price, higher software/service price) are reducing upfront revenue recognition in 2026/2027 but increasing long-term ARR and RPO visibility.
• ARR vs. Revenue Growth: Expect ARR growth to sustainably outpace revenue growth in 2027 and beyond as the recurring component expands.
• New Products & Upgrades: Expedite 3.0 is live; Express 11.0 is in beta with hundreds of thousands of users. Both are backward compatible with Gen 1 and Gen 2 hardware. New product tiers and form factors are in development to address more entrances and use cases.
• Adoption Metrics: Anticipate Expedite deployment growing beyond the current 9% of the customer base (up from 3% a year ago), particularly through renewals and upgrade offers. Net Revenue Retention (NRR) remains strong at 108%, with potential to drive NRR higher via renewals and expansions.
• Sales Capacity: Investment in frontline sellers is accelerating; new hires take several quarters to reach full productivity, with contributions expected to build through 2027 and become increasingly meaningful in 2028 and beyond.

Market and Competitive Outlook:

• Market Opportunity: Estimated 700,000 addressable doorways globally; current deployment of ~10,000 units represents <5% penetration, leaving significant runway.
• Competitive Advantages: Focus on improving detection while reducing false alerts to lower staffing barriers (friction reduction). Expedite 3.0 enhances threat isolation; Express 11.0 aims to maintain/improve detection while lowering alert rates.
• Vertical Trends:
  • Education: Deployed in 28 of the top 100 US school districts; added 12+ new customers in Q3 2026.
  • Healthcare: Represented 23% of units booked in Q3 2026 (up from 18% over the prior 12 months); presence in 800+ hospital buildings, including all 10 top healthcare networks.
  • Sports/Entertainment: Continued expansion at major venues and collegiate levels.
  • Corporate: Partner for 40+ Fortune 500 companies.
• Regulatory Tailwinds: California new standards requiring weapons detection screening at hospital entrants to be adopted by March 2027.

Macro / Industry Outlook:

• Regulatory Environment: Management views the regulatory backdrop as supportive, citing specific mandates (e.g., California) that create compliance-driven demand for screening solutions.
• International Expansion: Recognized as a future growth opportunity rather than a primary 2027 revenue driver; currently contributes ~4% of revenue. Ramp-up contingent on completing product and regulatory clearances (specifically for ionizing radiation in Expedite and data privacy in cloud platforms).
• Economic/Rate Context: No specific commentary on interest rates or FX provided; focus remains on internal pricing mix and sales capacity investments.

Strategic Initiatives:

• Sales & Marketing: Investing in frontline sales capacity and marketing to increase market presence and drive cross-sell into the existing install base.
• R&D: Continued investment in product innovation (e.g., Express 11.0, Expedite 3.0) to improve system performance and reduce friction.
• Infrastructure: Investments in IT systems and personnel to support scale and efficiency, including ongoing SOX remediation efforts.
• Funding: Growth investments will be funded by gross profit generated by the business and existing balance sheet; no external financing anticipated.

Risks and Headwinds to Outlook:

• Revenue Mix Headwind: 3–4 percentage point headwind to reported revenue growth in 2026/2027 due to the pricing shift moving value from one-time product revenue to recurring revenue recognized over the contract term (typically 4 years).
• Comparison Base Effects: First half of 2027 faces harder year-over-year comparisons compared to the first half of 2026, which benefited from direct fulfillment product revenue and significant backlog shipments.
• Ramp Timing: New frontline sellers and incremental unit deployments (expected in H2 2027) will delay the full impact of investments on revenue recognition and recurring revenue in the near term.
• International Ramp: Regulatory and compliance requirements for international markets could delay the realization of this growth opportunity.

Management Tone on the Future:

• Confidence Level: High confidence in the 2027 outlook (20%+ growth) and the long-term 25% CAGR through 2031.
• Strategic Shift: Management views the pricing restructuring (shifting to recurring) as a strategic improvement for long-term value and predictability, despite the near-term revenue recognition headwind.
• Financial Strength: Emphasis on funding growth through organic cash flow and positive adjusted EBITDA, maintaining discipline on profitability while prioritizing top-line expansion.

Miscellaneous:

• Investor Events: Scheduled appearances at the Craig Hallam Alpha Select Conference (next week), UBS Global Technology Conference (December), and Northland Capital Conference (later in December).
• RPO Visibility: Remaining Performance Obligation (RPO) stands at $325.8 million (up 12% YoY), representing 1.7x the full-year revenue outlook. Approximately $132 million of RPO is expected to recognize as revenue in the next 12 months. Embedded gross margin in RPO is estimated at 66%.